Quantitative Determination of Etoricoxib and Paracetamol in Pharmaceutical Dosage Form and in-vitro comparison by ReversedPhase High Performance Liquid Chromatography (RP-HPLC)
Keywords:
Paracetamol, Etoricoxib, RP-HPLC, In-vitro, Dissolution, HPLC, COX 2Abstract
The objective of this present work was to develop and validate analytical method for quantitative determination of Paracetamol and Etoricoxib in a tablet formulation and also the comparison of invitro data with reference dosage form. Chromatographic separations of the two drugs were analyzed on a Kromasil C18 column (25cm X 4.6mm, 5μm). The mobile phase constituted of Buffer: Acetonitirile with gradient program was delivered at the flow rate 1.0 mL/min. Detection was performed at 220 nm. Separation was completed within 20 min. Calibration curves were linear with coefficient correlation between 0.99 to 1.0 over a concentration range of 48 to 146 μg/mL of Paracetamol and 6 to 19 μg/mL for Etoricoxib respectively. The relative standard deviation (R.S.D) was found to be less than 2.0%. Analysis for dissolution study was also performed by Reversed-Phase High Performance Liquid Chromatography (RP-HPLC) method. Difference factor (f1) were found to be 2.85 and 3.83 and similarity factor (f2) were found to be 73.514 and 68.961 for Paracetamol and Etoricoxib respectively.
References
Shunta D, Martina KS, Vesta, TL, Ripley. A
highly selective COX-2 inhibitor, Annal.
Pharmaco, 2005; 39: 854-862.
Donnely MT, Hawkey CJ, Alim. Moleculartimetable methods for detection of body time
and rhythm disorders from single-time-point
genome-wide expression profiles. Pharmacol.
Thera., 1997;11:227.
Jouzeav JY, Terlinin B, Abid A. COX-II
inhibitors—a new generation of safer. NSAIDs
Drugs, 1997; 53:563.
Mitchell, Akarassereenant, Thiemermann. A
validated LC method for the quantitative
determination of celecoxib in pharmaceutical
dosage forms and purity evaluation in bulk
drugs. Proc Nat Acad Sci 1994, 1, 90.
Nageswara R, Rao S, Meena A, Raghuram
Rao. An overview of the recent developments
in analytical methodologies for determination
of COX-2 inhibitors in bulk drugs,
pharmaceuticals and biological matrices. J
Pharma Biomed Ana 2005, 39,349-363.
Matthews CZ, Woolf EJ, Lin L. Quantitative
determination of rofecoxib in pharmaceutical
preparations. J Chromatogr B Biomed. Sci
Appl 2001; 751: 237-239.
Mandal U, Senthil D, Bose A, Gowda KV,
Ghose A, Pal TK. Development and validation
of HPLC method for analysis of Etoricoxib in
human plasma, Ind J Pharma Sci 2006; 68(4):
-489.
Briautigam L, Jensu J, Geisslingle N.
Determination of Etoricoxib in human plasma
by liquid chromatography-tandem mass with
electro spray ionization. J Chromato 2003; 788:
-315.
Hartman R, Abrahim A, Clousen A, Crocker
LS, Ge Z. Development and validation of
HPLC method for impurity and Quantitative
analysis of etoricoxib. J Liq Chromato Rel
Techno 2003; 26: 2551-2566.
Ramakrishnan NV, Vishwottam KN, Wishnu
S, Koteshwra M. A stability-indicating high
performance liquid chromatographic (HPLC)
assay for the simultaneous determination of
atorvastatin and amlodipine in commercial
tablets J Chromato.B 2005; 816: 215-221.
Farneta JT, Agbaba D,.Eric S, Pavkov
S,.Aleksive M, Valdimirov S, HPLC assay of
acetylsalisylic acid, Paracetmol, Caffein and
Phenobarbital in tablet. IL Framco 2002;
:709-713.
Jensen LS, Velentine J, Milne RW, Evans AM.
The quantification of Paractamol,
Paracetamolglucuronid and Paracetamol
sulphate in plasma and urineusing HPLC
Assay. J Chromato 2002; 34: 585-593.
Anonymous, Bioanalytical method validation
guidance for industry. CDER, FDA, US. US
department of health and services, Rockville,
MD, 2001, p 209-10.
Anonymous, ICH Harmonized Tripartite
guidance for validation of analytical procedure:
Methodology, 1996, p 222-224.
